

ABSTRACT

The present invention relates to prophylactic antimigraine agents comprising as an active ingredient a dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors, the antagonist having a binding affinity selective for the 5-HT_{2B} and 5-HT₇ receptors.

5 Since these prophylactic antimigraine agents show an excellent pharmacological effect in comparison with the cases in which a 5-HT_{2B} receptor antagonist having a selective binding affinity to the 5-HT_{2B} receptor or a 5-HT₇ receptor antagonist having a selective binding affinity to the 5-HT₇ receptor is used alone, they are useful as drugs which are excellent in prophylaxis of migraine and in which the side effects found in the
10 existing prophylactic antimigraine agents are reduced.